Sterile injectables manufacturer Claris Lifesciences today said US health regulator has found its manufacturing facility acceptable after an inspection.
"Claris Lifesciences has announced that it has received a report from USFDA for the inspection it conducted classifying the finished dosage plant and the API plant as acceptable," the pharma company said in a BSE filing.
The company has three manufacturing plants at its campus on the outskirts of Ahmedabad.
The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.
